Gsa Capital Partners LLP Stoke Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$4.12 - $14.17 $18,947 - $65,167	-4,599 Reduced 4.5%	97,508 $1.32 Million
Q4 2023 Feb 16, 2024	SELL	$3.37 - $5.4 $828,891 - $1.33 Million	-245,962 Reduced 70.66%	102,107 $537,000
Q3 2023 Nov 15, 2023	BUY	$3.78 - $11.99 $1.1 Million - $3.49 Million	291,443 Added 514.68%	348,069 $1.37 Million
Q2 2023 Aug 14, 2023	BUY	$7.93 - $13.82 $128,957 - $224,740	16,262 Added 40.29%	56,626 $601,000
Q1 2023 May 12, 2023	SELL	$7.65 - $10.38 $238,741 - $323,939	-31,208 Reduced 43.6%	40,364 $336,000
Q4 2022 Feb 13, 2023	SELL	$7.07 - $15.69 $25,133 - $55,777	-3,555 Reduced 4.73%	71,572 $661,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $943,595 - $1.69 Million	75,127 New	75,127 $965,000
Q2 2022 Aug 09, 2022	SELL	$10.36 - $23.93 $419,528 - $969,045	-40,495 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$17.19 - $26.1 $275,521 - $418,330	16,028 Added 65.51%	40,495 $852,000
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $266,470 - $452,014	14,714 Added 150.87%	24,467 $587,000
Q3 2021 Nov 12, 2021	BUY	$23.65 - $34.44 $230,658 - $335,893	9,753 New	9,753 $248,000

117

55.6M

14K

8.8K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $482M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.